Report / Paper metadata
Phase II study of olaparib plus durvalumab in EGFR-mutant NSCLC transformed to small cell lung cancer.
A biomedical paper record. This page preserves its title, publication metadata and identifier, not the full article. The title alone does not establish the study findings or their clinical importance.
Limits
No clinical review has been performed. This record is not a treatment recommendation, eligibility confirmation or current availability guarantee.
- Kind
- Paper metadata